Utility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry
The expression of CCR7 in HRS cells suggests its potential utility in differentiating CHL from other B-cell lymphomas. Incorporating CCR7 into flow cytometry and IHC panels may further enhance the diagnostic sensitivity of CHL.
Authors
- Maria Tretiakova (ORCID: https://orcid.org/0000-0002-0819-9638)
- Jonathan R. Fromm (ORCID: https://orcid.org/0000-0002-2287-5284)
- Kikkeri N. Naresh (ORCID: https://orcid.org/0000-0003-3807-3638)
- Lori Soma (ORCID: https://orcid.org/0000-0003-0606-899X)
- Claire Murphy (ORCID: https://orcid.org/0000-0002-1382-7643)
- Xueyan Chen (ORCID: https://orcid.org/0000-0002-5435-0888)
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- City of Hope (US)
- Springfield Clinic (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1093/ajcp/aqae119
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.85